Antibody Name: M22 (VH SGIIID | VL kI)
References: Graziano, R., Tempest, P., White, P., Keler, T., Deo, Y., Ghebremariam, H., Coleman, K., Pfefferkorn, L., Fanger, M. and Guyre, P. "Construction and characterisation of a humanised anti-gamma-Ig receptor type 1 monoclonal antibody" J. Immunol. (1995) 155:4996-5002.
Donor Antibody: mouse
Acceptor Antibody: Human IgG1 | k
Antigen: human high affinity receptor for the Fc portion of IgG (FcγRI) (CD64)
Laboratory: Medarex, NJ; Scotgen Biopharmaceuticals, UK; Dartmouth Medical School, NH
Design: Fixed framework approach, except that KOL was included because of greater homology.
Frameworks: Tried VH FRs KOL (SGIII) and NEWM (SGII)
VL REI with M4L T39K V104L Q105E T107K
CDRs: All 6 VH and VL, Kabat Definition.
Backmutations: NEWM VH S27F T28I V71R
Binding: KOL/REI version gave same affinity as chimaeric as assessed by ELISA binding to FcγRI/IgM heavy chain fusion protein. Leukocyte binding analysis by flow cytometry confirmed identical specificity to mouse mAb.
Expression: mouse myeloma NS0
Comment: Bispecific constructs with 425 and anti-HIV mAbs being examined.
Clinical Indication: FcγRI-directed immunotherapy

explanation of symbols and abbreviations

José Saldanha © 1997-8. Birkbeck College, London WC1E 7HX.